Estrogen receptor expression in atypical hyperplasia: Lack of association with breast cancer

Cancer Prevention Research

Volumn 4, Issue 3, 2011, Pages 435-444

  Barr Fritcher, Emily G ^a   Degnim, Amy C ^a   Hartmann, Lynn C ^a   Radisky, Derek C ^b   Boughey, Judy C ^a   Anderson, Stephanie S ^a   Vierkant, Robert A ^a   Frost, Marlene H ^a   Visscher, Daniel W ^c   Reynolds, Carol ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST HYPERPLASIA; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVOLUTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNITED STATES;

AGED; BIOPSY; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, ESTROGEN; SEER PROGRAM; TREATMENT OUTCOME;

EID: 79955803865     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0242     Document Type: Article

References (29)

1. Howell A.Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer. Proceeding of the Royal Society of Edinburgh1989;95:49-57.
2. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47. (Pubitemid 23269069)
3. Allegra JC, Lippman ME, Green L, Barlock A, Simon R, Thompson EB, et al. Estrogen receptor values in patients with benign breast disease. Cancer 1979;44:228-31. (Pubitemid 9234936)
4. Petersen OW, Hoyer PE, van Deurs B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 1987;47:5748-51. (Pubitemid 18046775)
5. Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NS, Gazet JC, et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991;51:1817-22.
6. Visscher DW, Padaiyar N, Long D, Tabaczka P. Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions. Breast J 1998;4:447-51. (Pubitemid 29018658)
7. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999;188:237-44. (Pubitemid 29317764)
8. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999;155:1811-5.
9. Schmitt FC. Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis. Eur J Cancer 1995;31A:2049-52. (Pubitemid 26023096)
10. Shaaban AM, Sloane JP, West CR, Foster CS. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki- 67 expression. Am J Pathol 2002;160:597-604. (Pubitemid 34160337)
11. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62. (Pubitemid 41672231)
12. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-37. (Pubitemid 41058322)
13. Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 2007;25:2671-7. (Pubitemid 47123172)
14. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-708.
15. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992;23:1095-7.
16. Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, Maloney SD, et al. Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 2006;98:1600-7. (Pubitemid 44811643)
17. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocrine-related Cancer 2001;8:47-61. (Pubitemid 32520253)
18. Roger P, Daures JP, Maudelonde T, Pignodel C, Gleizes M, Chapelle J, et al. Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. Hum Pathol 2000;31:593-600. (Pubitemid 30323985)
19. Nonni A, Zagouri F, Sergentanis TN, Lazaris AC, Patsouris ES, Zografos GC. Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia. Virchows Arch 2007;451:893-7. (Pubitemid 350060748)
20. Middleton LP, Perkins GH, Tucker SL, Sahin AA, Singletary SE. Expression of ERalpha and ERbeta in lobular carcinoma in situ. Histopathology 2007;50:875-80. (Pubitemid 46850064)
21. Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC. Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res 2006;8:R6 (doi:10.1186/bcr1367).
22. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51. (Pubitemid 15192861)
23. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267:941-4.
24. Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009;9:51-60.
25. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
26. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, et al. Short-Term Breast Cancer Prediction by Random Periareolar Fine- Needle Aspiration Cytology and the Gail Risk Model. J Natl Cancer Inst 2000;92:1217-27.
27. Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001;116:495-503. (Pubitemid 34450283)
28. Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/ neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol 2004;121:620-30. (Pubitemid 38533993)
29. Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 2006;48:258-67.